CN1198613C - 氨基苯氧基乙酸衍生物和含有它们的药用组合物 - Google Patents
氨基苯氧基乙酸衍生物和含有它们的药用组合物 Download PDFInfo
- Publication number
- CN1198613C CN1198613C CNB998018171A CN99801817A CN1198613C CN 1198613 C CN1198613 C CN 1198613C CN B998018171 A CNB998018171 A CN B998018171A CN 99801817 A CN99801817 A CN 99801817A CN 1198613 C CN1198613 C CN 1198613C
- Authority
- CN
- China
- Prior art keywords
- amino
- methyl
- chemical compound
- piperidyl
- obtains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
化合物编号 | 幸存率(%)(化合物:1μM) | 化合物编号 | 幸存率(%)(化合物:1μM) |
38 | 114 | 94 | 198 |
40 | 108 | 95 | 61 |
41 | 86 | 96 | 91 |
42 | 131 | 97 | 119 |
44 | 93 | 98 | 120 |
45 | 190 | 99 | 151 |
46 | 101 | 100 | 138 |
48 | 207 | 101 | 138 |
49 | 193 | 102 | 89 |
50 | 54 | 103 | 180 |
53 | 144 | 104 | 117 |
60 | 60 | 105 | 86 |
61 | 58 | 106 | 151 |
62 | 63 | 107 | 227 |
65 | 73 | 109 | 76 |
66 | 60 | 110 | 61 |
67 | 69 | 111 | 84 |
68 | 75 | 112 | 76 |
69 | 68 | 113 | 74 |
70 | 88 | 114 | 50 |
71 | 89 | 116 | 59 |
74 | 87 | 119 | 115 |
75 | 96 | 120 | 88 |
76 | 106 | 121 | 82 |
77 | 111 | 124 | 86 |
78 | 96 | 125 | 52 |
79 | 79 | 126 | 47 |
80 | 99 | 127 | 72 |
81 | 97 | 128 | 81 |
82 | 149 | 129 | 64 |
83 | 65 | 130 | 60 |
84 | 87 | 131 | 65 |
85 | 98 | 132 | 60 |
86 | 127 | 133 | 101 |
87 | 81 | 134 | 79 |
88 | 81 | 135 | 76 |
89 | 126 | 136 | 81 |
90 | 149 | 137 | 71 |
91 | 203 | 138 | 42 |
92 | 66 | 139 | 53 |
93 | 171 |
化合物编号 | 诱导钙结合蛋白D28Kd的量(%相对于对照组)(化合物:1μM) |
29 | 122 |
40 | 150 |
111 | 167 |
128 | 171 |
对照组 | 100 |
化合物编号(给药量) | 脑水肿抑制率(%) |
29(3mg/kg) | 30.9 |
40(1mg/kg) | 31.1 |
40(3mg/kg) | 20.5 |
42(1mg/kg) | 24.5 |
42(3mg/kg) | 31.0 |
104(3mg/kg) | 18.9 |
105(3mg/kg) | 23.2 |
108(3mg/kg) | 20.3 |
109(3mg/kg) | 24.7 |
111(3mg/kg) | 25.0 |
112(3mg/kg) | 20.7 |
113(3mg/kg) | 20.0 |
119(1mg/kg) | 21.6 |
128(3mg/kg) | 20.3 |
132(1mg/kg) | 30.4 |
134(1mg/kg) | 27.9 |
134(3mg/kg) | 35.0 |
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29488698 | 1998-10-16 | ||
JP294886/1998 | 1998-10-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1287487A CN1287487A (zh) | 2001-03-14 |
CN1198613C true CN1198613C (zh) | 2005-04-27 |
Family
ID=17813532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998018171A Expired - Fee Related CN1198613C (zh) | 1998-10-16 | 1999-10-14 | 氨基苯氧基乙酸衍生物和含有它们的药用组合物 |
Country Status (12)
Country | Link |
---|---|
US (3) | US6559146B1 (zh) |
EP (1) | EP1045693B1 (zh) |
JP (1) | JP2002527477A (zh) |
KR (1) | KR100676109B1 (zh) |
CN (1) | CN1198613C (zh) |
AT (1) | ATE270103T1 (zh) |
AU (1) | AU762345B2 (zh) |
CA (1) | CA2315050C (zh) |
DE (1) | DE69918404T2 (zh) |
ES (1) | ES2221440T3 (zh) |
HU (1) | HUP0100819A3 (zh) |
WO (1) | WO2000023076A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7743016B2 (en) | 2005-10-05 | 2010-06-22 | Lg Electronics Inc. | Method and apparatus for data processing and encoding and decoding method, and apparatus therefor |
US7774199B2 (en) | 2005-10-05 | 2010-08-10 | Lg Electronics Inc. | Signal processing using pilot based coding |
US7865369B2 (en) | 2006-01-13 | 2011-01-04 | Lg Electronics Inc. | Method and apparatus for signal processing and encoding and decoding method, and apparatus therefor |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1198613C (zh) * | 1998-10-16 | 2005-04-27 | 第一三得利制药株式会社 | 氨基苯氧基乙酸衍生物和含有它们的药用组合物 |
SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
ATE348808T1 (de) | 2000-03-06 | 2007-01-15 | Acadia Pharm Inc | Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten |
JP2004501079A (ja) * | 2000-04-13 | 2004-01-15 | 第一サントリーファーマ株式会社 | アミノフェノキシアセタミド誘導体並びにそれらを含む医薬 |
ATE398109T1 (de) * | 2000-08-08 | 2008-07-15 | Ortho Mcneil Pharm Inc | 4-pyrimidinamine derivate, pharmazeutische zusammenstellungen und verwandte methoden |
US6376514B1 (en) * | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
US6693099B2 (en) * | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
US20030186963A1 (en) * | 2001-09-14 | 2003-10-02 | Dorwald Florencio Zaragoza | Substituted piperidines |
SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
EP1461339B1 (en) | 2001-12-28 | 2010-04-28 | Acadia Pharmaceuticals Inc. | Spiroazacyclic compounds as monoamine receptor modulators |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
CA2490397A1 (en) | 2002-06-24 | 2003-12-31 | Acadia Pharmaceuticals Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
CN1816524B (zh) | 2003-01-16 | 2012-06-27 | 阿卡蒂亚药品公司 | 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂 |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
BRPI0512535A (pt) | 2004-06-24 | 2008-03-25 | Incyte Corp | compostos de piperidinas n-substituìdas, suas composições e métodos de modulações |
US7687665B2 (en) | 2004-06-24 | 2010-03-30 | Incyte Corporation | 2-methylprop anamides and their use as pharmaceuticals |
EP2289879B1 (en) | 2004-09-27 | 2014-11-12 | Acadia Pharmaceuticals Inc. | Synthesis of a crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
TW200815353A (en) * | 2006-04-13 | 2008-04-01 | Euro Celtique Sa | Benzenesulfonamide compounds and their use |
US8937181B2 (en) * | 2006-04-13 | 2015-01-20 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
CA2681506C (en) | 2007-03-19 | 2016-05-24 | Perry Peters | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
CN103396399B (zh) * | 2007-04-27 | 2015-04-29 | 第一三共株式会社 | 含氮芳香族六元环衍生物及含有它们的药物 |
US8765736B2 (en) * | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
PT3325444T (pt) | 2015-07-20 | 2021-09-22 | Acadia Pharm Inc | Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
ES2913929T3 (es) * | 2016-06-08 | 2022-06-06 | Glaxosmithkline Ip Dev Ltd | Compuestos químicos como inhibidores de la ruta de ATF4 |
EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
EP3615028A1 (en) | 2017-04-28 | 2020-03-04 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
MX2020001352A (es) | 2017-08-09 | 2020-03-20 | Denali Therapeutics Inc | Compuestos, composiciones y metodos. |
US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
EP3768660A1 (en) * | 2018-03-23 | 2021-01-27 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
CR20210426A (es) | 2019-02-13 | 2021-09-30 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5214147A (en) * | 1987-08-12 | 1993-05-25 | Elf Atochem North America, Inc. | Process for preparing reactive hindered amine light stabilizers |
DE3854991T2 (de) * | 1987-11-27 | 1996-07-18 | Eisai Co Ltd | Cyclische Amine und pharmakologische Verbindungen |
DE4032766A1 (de) | 1990-10-16 | 1992-04-30 | Basf Ag | Phenylpiperidinoylamine und diese enthaltende arzneimittel |
IL105716A0 (en) | 1992-06-08 | 1993-09-22 | Richter Gedeon Vegyeszet | Aminopropanol derivatives,their preparation and pharmaceutical compositions containing them |
KR19990037220A (ko) * | 1997-10-31 | 1999-05-25 | 타이도 나오카타 | 아릴아세트산 아미드 유도체 또는 그 염 및 이를 함유하는 의약 |
CN1198613C (zh) * | 1998-10-16 | 2005-04-27 | 第一三得利制药株式会社 | 氨基苯氧基乙酸衍生物和含有它们的药用组合物 |
-
1999
- 1999-10-14 CN CNB998018171A patent/CN1198613C/zh not_active Expired - Fee Related
- 1999-10-14 HU HU0100819A patent/HUP0100819A3/hu unknown
- 1999-10-14 AU AU61226/99A patent/AU762345B2/en not_active Ceased
- 1999-10-14 KR KR1020007006551A patent/KR100676109B1/ko not_active IP Right Cessation
- 1999-10-14 ES ES99947887T patent/ES2221440T3/es not_active Expired - Lifetime
- 1999-10-14 EP EP99947887A patent/EP1045693B1/en not_active Expired - Lifetime
- 1999-10-14 DE DE69918404T patent/DE69918404T2/de not_active Expired - Lifetime
- 1999-10-14 CA CA002315050A patent/CA2315050C/en not_active Expired - Fee Related
- 1999-10-14 JP JP2000576850A patent/JP2002527477A/ja not_active Abandoned
- 1999-10-14 AT AT99947887T patent/ATE270103T1/de not_active IP Right Cessation
- 1999-10-14 US US09/581,756 patent/US6559146B1/en not_active Expired - Fee Related
- 1999-10-14 WO PCT/JP1999/005658 patent/WO2000023076A1/en not_active Application Discontinuation
-
2003
- 2003-03-24 US US10/394,221 patent/US6998401B2/en not_active Expired - Fee Related
-
2005
- 2005-07-06 US US11/174,575 patent/US7488738B2/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7743016B2 (en) | 2005-10-05 | 2010-06-22 | Lg Electronics Inc. | Method and apparatus for data processing and encoding and decoding method, and apparatus therefor |
US7756702B2 (en) | 2005-10-05 | 2010-07-13 | Lg Electronics Inc. | Signal processing using pilot based coding |
US7756701B2 (en) | 2005-10-05 | 2010-07-13 | Lg Electronics Inc. | Audio signal processing using pilot based coding |
US7774199B2 (en) | 2005-10-05 | 2010-08-10 | Lg Electronics Inc. | Signal processing using pilot based coding |
US8068569B2 (en) | 2005-10-05 | 2011-11-29 | Lg Electronics, Inc. | Method and apparatus for signal processing and encoding and decoding |
US7865369B2 (en) | 2006-01-13 | 2011-01-04 | Lg Electronics Inc. | Method and apparatus for signal processing and encoding and decoding method, and apparatus therefor |
Also Published As
Publication number | Publication date |
---|---|
US6998401B2 (en) | 2006-02-14 |
EP1045693A1 (en) | 2000-10-25 |
EP1045693B1 (en) | 2004-06-30 |
US20050245574A1 (en) | 2005-11-03 |
ES2221440T3 (es) | 2004-12-16 |
CA2315050C (en) | 2009-02-03 |
KR100676109B1 (ko) | 2007-02-01 |
HUP0100819A3 (en) | 2002-12-28 |
US7488738B2 (en) | 2009-02-10 |
WO2000023076A1 (en) | 2000-04-27 |
DE69918404D1 (de) | 2004-08-05 |
HUP0100819A2 (hu) | 2001-08-28 |
AU6122699A (en) | 2000-05-08 |
US6559146B1 (en) | 2003-05-06 |
CA2315050A1 (en) | 2000-04-27 |
DE69918404T2 (de) | 2005-08-04 |
CN1287487A (zh) | 2001-03-14 |
ATE270103T1 (de) | 2004-07-15 |
US20040063748A1 (en) | 2004-04-01 |
AU762345B2 (en) | 2003-06-26 |
JP2002527477A (ja) | 2002-08-27 |
KR20010033169A (ko) | 2001-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1198613C (zh) | 氨基苯氧基乙酸衍生物和含有它们的药用组合物 | |
CN1043639C (zh) | 新的哌啶化合物、其制备方法和含有它们的药用组合物 | |
CN100338036C (zh) | 对激酶及细胞周期蛋白复合物具有抑制作用的取代的吲哚满酮 | |
CN1158258C (zh) | 肾上腺素能α1B受体拮抗药 | |
CN1184208C (zh) | 取代的苯并咪唑及其制备和用途 | |
CN1192773C (zh) | 环胺ccr3拮抗剂 | |
CN1115330C (zh) | N-(4-脒基苯基)甘氨酰胺衍生物 | |
CN1476434A (zh) | 新化合物 | |
CN1107839A (zh) | 甲酰胺类化合物 | |
CN101050194A (zh) | 双环辛烷类衍生物、其制备方法及其在医药上的用途 | |
CN1038641A (zh) | 取代的4-(喹啉-2-基-甲氧基)苯乙酸衍生物 | |
CN1434811A (zh) | 用于治疗炎性、免疫或心血管疾病的新的p2x7受体拮抗剂 | |
CN1376156A (zh) | 苯并二氮杂䓬衍生物、其制备和用途 | |
CN1929834A (zh) | 吲哚-1-基乙酸衍生物 | |
CN1812980A (zh) | 哌啶基-和哌嗪基-烷基氨基甲酸酯衍生物,其制备及治疗用途 | |
CN1129937A (zh) | 作为5ht2c拮抗剂的二氢吲哚衍生物 | |
CN1059908A (zh) | 嘧啶衍生物及其药物 | |
CN1064273A (zh) | 新的具有ngf生成促进活性的苯衍生物 | |
CN101080392A (zh) | 作为抗肥胖药剂的哌嗪基吡啶衍生物 | |
CN1204889C (zh) | 粘附受体拮抗剂 | |
CN1320123A (zh) | 二取代马来酰亚胺化合物及其医药用途 | |
CN1011780B (zh) | 苯氧基乙酸衍生物的制备方法 | |
CN1079962A (zh) | 新型取代叔胺化合物及其盐 | |
CN1878750A (zh) | 芳基烷基氨基甲酸酯衍生物、其制备方法和其在治疗学中的用途 | |
CN1458922A (zh) | 尿素衍生物及以其作为有效成分的粘连分子阻断剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SUNTORY LTD Free format text: FORMER OWNER: SUNTORY LTD. Effective date: 20030410 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20030410 Address after: Tokyo, Japan, Japan Applicant after: Daiichi Suntory Pharma Co., Ltd. Address before: Osaka City, Osaka of Japan Applicant before: Suntory Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: THE FIRST ASHBIAO PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: SUNTORY LTD |
|
CP03 | Change of name, title or address |
Address after: Tokyo, Japan, Japan Patentee after: Daiichi Asubio Pharma Co., Ltd. Address before: Tokyo, Japan, Japan Patentee before: Daiichi Suntory Pharma Co., Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: ASTERIX PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: THE FIRST ASHBIAO PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: Tokyo, Japan Patentee after: Asubio Pharma Co., Ltd. Address before: Tokyo, Japan, Japan Patentee before: Daiichi Asubio Pharma Co., Ltd. |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050427 Termination date: 20101014 |